OncoXome develops cancer treatments by targeting widespread cancer cells using a promising drug delivery system loaded with cutting-edge therapy. This approach is designed to block cancer cell resistance mechanisms and induce cell death while minimizing patient side effects. The company focuses on disrupting the complex ecosystem of cancer cell communication mediated by exosomes.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers develop resistance to conventional treatments by using intercellular communication to adapt and evade therapeutic interventions. This resistance often involves the exchange of information via exosomes, which are extracellular vesicles that transfer drug-resistance capabilities between cancer cells. Current cancer therapies often fail to adequately address this communication-driven resistance, leading to treatment failure and disease progression.
Solution
OncoXome is developing a novel therapeutic approach that leverages natural exosomes to deliver gene therapies directly to cancer cells, disrupting their communication networks and inducing cell death. By targeting the mechanisms that enable cancer cells to share resistance traits, OncoXome's technology aims to prevent the development of treatment resistance. This approach involves loading exosomes with gene-editing payloads designed to block resistance mechanisms and trigger apoptosis in targeted cancer cells. The goal is to improve patient outcomes by enhancing treatment efficacy and minimizing side effects associated with traditional cancer therapies.
Target Audience
OncoXome's primary target audience includes late-stage cancer patients with widespread cancer cells that have developed resistance to conventional treatments, as well as oncologists and researchers seeking innovative therapeutic strategies.
Features
- Utilizes natural exosomes for targeted drug delivery to cancer cells.
- Employs gene therapy to disrupt cancer cell communication and block resistance mechanisms.
- Focuses on preventing the development of treatment resistance in cancer cells.
- Aims to induce apoptosis (cell death) in targeted cancer cells.
- Designed to limit side effects compared to traditional cancer treatments.